In a clinical trial to assess the efficiency of a new medication named CT1812 for AD, fluorodeoxyglucose (FDG) PET, synaptic vesicle glycoprotein 2 A (SV2A), and volumetric MRI were utilized to measure the changes over 24 weeks (van Dyck et al., 2024). Here, SV2A is linked to Alzheimer disease.